Hi again
خبر جيد جدا
Independent Study Shows Lifestream Technologies' Cholesterol Monitor to
Be as Accurate as Physician's Office Test
Monday July 19, 6:30 am ET
Consumers Can Trust Home Test Results
POST FALLS, Idaho--(BUSINESS WIRE)--July 19, 2004--Lifestream Technologies, Inc. (OTCBB:LFTC - News), the leading manufacturer of home cholesterol monitors and professional screening devices, today announced that an independent accuracy and precision study was conducted by Radiant Research, Inc., comparing the Lifestream Cholesterol Monitor against three professional methods: a physician's office lab system, a local independent lab, and the Abell-Kendall method, the US government accuracy and precision standard for all cholesterol test devices.
"It is extremely important that we determine accuracy of at-home testing," stated Dr. Michael Davidson, Medical Director for Radiant Research. "At-home testing provides an opportunity for patients to assume more control of their overall health. If patients can identify the problem early on, they can work with their physician to initiate treatment."
This independent study was conducted at Radiant's Tucson, Arizona, facility under strict scientific controls with trial protocol approved by an Institutional Review Board. The study assessed Lifestream's home cholesterol monitor against an independent lab, a popular physician's office lab system, and the CDC-controlled standard, the Abell-Kendall technique, at a Cholesterol Reference Method Lab. A copy of the study results are available on Lifestream's website at
http://www.knowitforlife.com/proresources.asp or by email at
gerriv@lifestreamtech.com.
"This study was motivated by recent articles, which implied that results provided by home cholesterol test devices were inaccurate," stated Christopher Maus, Lifestream's President and CEO. "These articles' conclusions, based on non-scientific testing procedures, were assumptive at best and conducted in a casual manner leading the reader to an erroneous conclusion. This journalist approach misleads the public. Although we don't believe any particular media group would intentionally utilize what, in scientific circles, would be considered "junk science," we are trying to reassure the public as to what pure science says about Lifestream's product. The Radiant Research study's conclusions proved that test results obtained with Lifestream's cholesterol monitor were as accurate and precise as the results obtained from a physician's office or an independent lab."
The National Cholesterol Education Program (NCEP) has concluded that home testing can be an important tool in improving adherence to cholesterol programs. Separate studies indicate that as few as 30% of patients remain on statin medication after one year. Home testing has proven to be effective in monitoring blood pressure and glucose; now, it is also effective in cholesterol management programs.
"The results of this preliminary study are clear and unambiguous," stated Jackson Connolly, Lifestream's VP Product Development. "Under strict scientific evaluation protocols and lab practices, the Lifestream Cholesterol Monitor's results prove as accurate as test results received from a physician's office. To further confirm this, a number of other universities are preparing to replicate this study to confirm the results. It is expected that the results of this expanded study will encourage the media to use good journalistic practices relying on scientific literature rather than relying on misleading outcomes from nonscientific methods. We expect the expanded study results to be submitted to important peer review journals."
About Radiant Research
Based near Seattle, Radiant Research (
http://www.radiantresearch.com) is a comprehensive clinical research company that provides Phase I-IV clinical drug development services to the biopharmaceutical and medical device industry. Radiant is comprised of more than 50 wholly owned premier clinical research sites nationwide, employing over 1,000 research professionals exclusively focused on providing professional, high-quality comprehensive clinical research services. In the past four years, Radiant has conducted more than 8,400 clinical trials across 18 therapeutic specialties. Radiant's client list includes every major pharmaceutical company and contract research organization and many biotechnology and medical device companies.
About Lifestream Technologies
The Company developed and currently markets a line of cholesterol monitors to consumers and healthcare professionals that provide test results in three minutes.
The Company's product line aids the health-conscious consumer in monitoring their risk of heart disease. By regularly testing cholesterol at home, individuals can monitor the benefits of their diet, exercise and/or drug therapy programs. Monitoring these benefits can support the physician and the individual's efforts to improve compliance. Lifestream's products also integrate a smart card reader further supporting compliance by storing test results on an individual's personal health card for future retrieval, trend analysis and assessment.
Lifestream's monitors are affordable, hand-held devices that provide users with accurate results in less than three minutes. The product line has been designed to accommodate The Data Concern(TM) Personal Health Card® allowing multiple users the ability to store their personal results. Lifestream's products are now available in pharmacy and retail outlets nationwide. To find retailers that carry Lifestream's products, go to "Store Locator" on
www.knowitforlife.com or contact Customer Care at 888-954-LIFE. For Company information, visit
www.lifestreamtech.com.
This news release includes certain forward-looking statements within the meaning of the safe harbor protections of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements regarding our current business plans, strategies and objectives that involve risks and uncertainties, and, in particular, statements referring to our expectations for increased market penetration and improved gross margins from our recently introduced second-generation consumer monitors and statements regarding our expectations that we can obtain necessary additional financing and investment. These forward-looking statements involve risks and uncertainties that could cause actual results to differ from anticipated results. The forward-looking statements are based on our current expectations and what we believe are reasonable assumptions given our knowledge of the relevant markets; however, our actual performance, results and achievements could differ materially from those expressed in, or implied by, these forward-looking statements. Factors, within and beyond our control, that could cause or contribute to such differences include, among others, the following: the success of our capital-raising and cost-cutting efforts, developing and marketing relatively new medical diagnostic devices, including technological advancements and innovations; consumer receptivity and preferences; availability, affordability and coverage terms of private and public medical insurance; political and regulatory environments and general economic and business conditions; the effects of our competition; the success of our operating, marketing and growth initiatives; development and operating costs; the amount and effectiveness of our advertising and promotional efforts; brand awareness; the existence of adverse publicity; changes in business strategies or development plans; quality and experience of our management; availability, terms and deployment of capital; labor and employee benefit costs; as well as those factors discussed in our most recent Registration Statement on Form SB-2 filed June 10, 2004, and in "Item 1 -- Our Business," "Item 6 -- Our Management's Discussion and Analysis," particularly the discussion under "Risk Factors -- Substantial Doubt as to our Ability to Continue as a Going Concern" and elsewhere in our most recent Annual Report on Form 10-KSB for our fiscal year ended June 30, 2003, both filed with the United States Securities and Exchange Commission. Readers are urged to carefully review and consider the various disclosures made by us in this report, in the aforementioned Form SB-2 and Form 10-KSB, and those detailed from time to time in our other reports and filings with the United States Securities and Exchange Commission that attempt to advise interested parties of the risks and factors that are likely to affect our business.